Blood test detects colorectal cancer recurrence earlier than imaging in stage III patients

▪ SCREENING

Blood test detects colorectal cancer recurrence earlier than imaging in stage III patients — Cancer Diagnosis & Prognosis

A retrospective case series of four patients with stage III colorectal cancer demonstrated the clinical utility of the Signatera assay, a personalized circulating tumor DNA (ctDNA) test. The assay detected minimal residual disease (MRD) and predicted recurrence earlier than traditional imaging scans. Signatera is a tumor-informed ctDNA test that reports results in mean tumor molecules per milliliter (MTM/ml), offering dynamic monitoring beyond traditional mutant allele frequency methods.